MM09
/ Inmunotek
- LARVOL DELTA
Home
Next
Prev
1 to 14
Of
14
Go to page
1
May 13, 2025
MM09-SIT-023: Efficacy and Safety Evaluation for the Treatment of Allergy Against Mites
(clinicaltrials.gov)
- P3 | N=150 | Recruiting | Sponsor: Inmunotek S.L. | Trial completion date: Dec 2025 ➔ Dec 2026 | Trial primary completion date: Jan 2024 ➔ Dec 2026
Trial completion date • Trial primary completion date • Allergy • Asthma • Conjunctivitis • Immunology • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology • Pulmonary Disease • Respiratory Diseases
December 19, 2023
Efficacy and Safety Evaluation for the Treatment of Asthma and Allergic Rhinitis/Rhinoconjunctivitis
(clinicaltrials.gov)
- P3 | N=18 | Terminated | Sponsor: Inmunotek S.L. | N=140 ➔ 18 | Recruiting ➔ Terminated; Due to the low recruitment rate since the start of the trial
Enrollment change • Monotherapy • Trial termination • Allergic Rhinitis • Allergy • Asthma • Conjunctivitis • Immunology • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology • Pulmonary Disease • Respiratory Diseases
October 23, 2023
MM09-SLIM: Clinical Trial to Evaluate the Efficacy and Safety of Polymerized, Mannan-Conjugated Dermatophagoides Allergen Extract
(clinicaltrials.gov)
- P2/3 | N=90 | Not yet recruiting | Sponsor: Inmunotek S.L. | Trial completion date: Dec 2025 ➔ Dec 2026 | Initiation date: Apr 2023 ➔ Nov 2023 | Trial primary completion date: Jun 2025 ➔ Jun 2026
Trial completion date • Trial initiation date • Trial primary completion date • Allergic Rhinitis • Allergy • Asthma • Conjunctivitis • Immunology • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology • Pulmonary Disease • Respiratory Diseases
December 07, 2022
MM09-SLIM: Clinical Trial to Evaluate the Efficacy and Safety of Polymerized, Mannan-Conjugated Dermatophagoides Allergen Extract
(clinicaltrials.gov)
- P2/3 | N=90 | Not yet recruiting | Sponsor: Inmunotek S.L.
New P2/3 trial • Allergic Rhinitis • Allergy • Asthma • Conjunctivitis • Immunology • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology • Pulmonary Disease • Respiratory Diseases
November 18, 2022
Efficacy and Safety Evaluation for the Treatment of HDM Induced Allergic Asthma and Rhinitis/Rhinoconjunctivitis
(clinicaltrials.gov)
- P3 | N=400 | Not yet recruiting | Sponsor: Inmunotek S.L. | Initiation date: Aug 2022 ➔ Dec 2022
Trial initiation date • Allergic Rhinitis • Allergy • Asthma • Conjunctivitis • Immunology • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology • Pulmonary Disease • Respiratory Diseases
August 03, 2022
Efficacy and Safety Evaluation for the Treatment of Asthma and Allergic Rhinitis/Rhinoconjunctivitis
(clinicaltrials.gov)
- P3 | N=140 | Recruiting | Sponsor: Inmunotek S.L. | Trial completion date: Sep 2022 ➔ Oct 2023 | Trial primary completion date: Sep 2022 ➔ Oct 2023
Trial completion date • Trial primary completion date • Allergic Rhinitis • Allergy • Asthma • Conjunctivitis • Immunology • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology • Pulmonary Disease • Respiratory Diseases
June 02, 2022
Efficacy and Safety Evaluation for the Treatment of HDM Induced Allergic Asthma and Rhinitis/Rhinoconjunctivitis
(clinicaltrials.gov)
- P3 | N=400 | Not yet recruiting | Sponsor: Inmunotek S.L.
New P3 trial • Allergic Rhinitis • Allergy • Asthma • Conjunctivitis • Immunology • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology • Pulmonary Disease • Respiratory Diseases
March 24, 2022
MM09-SIT-023: Efficacy and Safety Evaluation for the Treatment of Allergy Against Mites
(clinicaltrials.gov)
- P3 | N=150 | Recruiting | Sponsor: Inmunotek S.L. | Trial completion date: Apr 2022 ➔ Dec 2025 | Trial primary completion date: Jan 2022 ➔ Jan 2024
Trial completion date • Trial primary completion date • Allergy • Asthma • Conjunctivitis • Immunology • Ocular Infections • Ocular Inflammation • Ophthalmology • Pulmonary Disease • Respiratory Diseases
September 22, 2021
Efficacy and Safety Evaluation for the Treatment of Asthma and Allergic Rhinitis/Rhinoconjunctivitis
(clinicaltrials.gov)
- P3; N=140; Recruiting; Sponsor: Inmunotek S.L.; Active, not recruiting ➔ Recruiting
Clinical • Enrollment open • Monotherapy • Allergic Rhinitis • Allergy • Asthma • Conjunctivitis • Immunology • Ocular Infections • Ocular Inflammation • Ophthalmology • Pulmonary Disease • Respiratory Diseases
May 28, 2021
Efficacy and Safety Evaluation for the Treatment of Asthma and Allergic Rhinitis/Rhinoconjunctivitis
(clinicaltrials.gov)
- P3; N=140; Active, not recruiting; Sponsor: Inmunotek S.L.; Not yet recruiting ➔ Active, not recruiting
Clinical • Enrollment closed • Monotherapy • Allergic Rhinitis • Allergy • Asthma • Conjunctivitis • Immunology • Ocular Infections • Ocular Inflammation • Ophthalmology • Pulmonary Disease • Respiratory Diseases
May 25, 2021
MM09-SIT-023: Efficacy and Safety Evaluation for the Treatment of Allergy Against Mites
(clinicaltrials.gov)
- P3; N=150; Recruiting; Sponsor: Inmunotek S.L.; Trial primary completion date: Jan 2021 ➔ Jan 2022
Clinical • Trial primary completion date • Allergy • Asthma • Conjunctivitis • Immunology • Ocular Infections • Ocular Inflammation • Ophthalmology • Pulmonary Disease • Respiratory Diseases
May 06, 2021
Efficacy and Safety Evaluation for the Treatment of Asthma and Allergic Rhinitis/Rhinoconjunctivitis
(clinicaltrials.gov)
- P3; N=140; Not yet recruiting; Sponsor: Inmunotek S.L.
Clinical • Monotherapy • New P3 trial • Allergic Rhinitis • Allergy • Asthma • Conjunctivitis • Immunology • Ocular Infections • Ocular Inflammation • Ophthalmology • Pulmonary Disease • Respiratory Diseases
November 02, 2020
MM09-SIT-023: Efficacy and Safety Evaluation for the Treatment of Allergy Against Mites
(clinicaltrials.gov)
- P3; N=150; Recruiting; Sponsor: Inmunotek S.L.; Not yet recruiting ➔ Recruiting
Clinical • Enrollment open • Allergy • Asthma • Conjunctivitis • Immunology • Ocular Inflammation • Ophthalmology • Respiratory Diseases
June 17, 2020
MM09-SIT-023: Efficacy and Safety Evaluation for the Treatment of Allergy Against Mites
(clinicaltrials.gov)
- P3; N=150; Not yet recruiting; Sponsor: Inmunotek S.L.
Clinical • New P3 trial • Allergy • Asthma • Conjunctivitis • Immunology • Ocular Infections • Ocular Inflammation • Ophthalmology • Respiratory Diseases
1 to 14
Of
14
Go to page
1